GIP and fatty liver disease: This prospective, non-randomized pilot study provides preliminary evidence that the combination of TZP, a dual GIP/GLP-1 receptor agonist, with LEKT leads to significantly greater reductions in hepatic steatosis and stiffness, assessed by FibroScan®, compared to TZP combined with a standard LCD in patients with MASLD.